Arcturus Therapeutics Holdings Inc. ARCT is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies. San Diego, CA-based Arcturus has ...

XBB.1.16 Arcturus symptoms According to Schaffner, there have been “a slew of anecdotal reports" from doctors that the XBB.1.16 variant may be causing a few distinct and unusual symptoms ...

Health chiefs first detected 'Arcturus', a highly infectious spin-off of Omicron, in New York in late January. But it has since spread to 26 more states and triggered 235 cases, with hotspots ...

Arcturus is responsible for a surge in COVID case counts in some parts of the world, including India, where itchy or “sticky” eyes have been most frequently reported in children, along with ...

Arcturus, also known as XBB.1.16, has also attracted attention after reports linking it to what has been a rare COVID-19 symptom: pink eye.

New COVID-19 Strain Arcturus May Cause Pink Eye, L.A. County Health Officials Say Los Angeles County Department of Public Health confirmed three cases of the Arcturus strain with "observational ...

Arcturus Therapeutics ARCT 0.0% announced this morning that it has initiated dosing of its Covid-19 vaccine candidate—LUNAR COV-19, (ARCT-021)—in a Phase 1/2 study in collaboration with Duke ...

Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson ...

Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates.

Friday, Arcturus Therapeutics Holdings Inc ARCT presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with cystic fibrosis for ARCT-032, an inhaled investigational ...

News New COVID mutation called Arcturus is producing two new symptoms in children: report Updated: Apr. 27, 2023, 7:06 a.m. | Published: Apr. 27, 2023, 5:15 a.m.